Janssen Search
Search results
Diversity, Equity & Inclusion In Action
Diversity, Equity & Inclusion In Action Turning Data into Measurable, Viable Results Johnson & Johnson aspires to help eradicate racial and social injustice as a public health threat by eliminating health inequities for people of color. For this ...
Johnson & Johnson is transforming solid tumor cancer outcomes with new data at the 2024 World Conference on Lung Cancer and European Society for Medical Oncology Congress
Aug 27, 2024 United States Four RYBREVANT ® (amivantamab-vmjw) studies feature compelling new findings in lung and colorectal cancers New TAR-200 data reveal the potential of organ-sparing therapy for the treatment of bladder cancer RARITAN, NJ, August ...
Findings from landmark RESONATE-2 study confirm sustained survival benefit of IMBRUVICA® (ibrutinib) for first-line chronic lymphocytic leukaemia treatment with up to 10 years follow-up
Jun 14, 2024 RESONATE-2 data presented at the 2024 European Hematology Association (EHA) Congress provide longest-term outcomes and safety data ever reported for a monotherapy BTK inhibitor, with a median progression-free survival of 8.9 years 1 ...
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet therapy regimen shows significant improvement in outcomes for patients with transplant-eligible newly diagnosed multiple myeloma
Dec 12, 2023 United States DARZALEX FASPRO ®-based induction, consolidation and maintenance regimen reduced risk of progression or death by 58 percent compared to standard of care regimen First presentation of data from Phase 3 PERSEUS study highlighted ...
Retinal Disease
Retinal Disease Our Expansive Legacy At Janssen, patient needs set the priorities. We have a legacy of entering spaces with innovations that transform lives. From young children to those young at heart, our commitment to eye diseases is no exception. We ...
Avrum Spira, M.D., M.Sc.
AVRUM SPIRA, M.D., M.Sc. GLOBAL HEAD LUNG CANCER INITIATIVE AT JOHNSON & JOHNSON AND WORLD WITHOUT DISEASE ACCELERATOR Avrum “Avi” Spira, M.D., M.Sc. is the Global Head of Johnson & Johnson’s cross-sector Lung Cancer Initiative (LCI). The vision ...
Why it’s Important to Celebrate International Women’s Day
Why it’s Important to Celebrate International Women’s Day Recently, we celebrated International Women's Day (IWD), a global awareness day paying special tribute to the social, economic, cultural and political achievements of women. IWD is ...
Machine Learning
By leveraging state-of-the-art machine learning techniques to recognize complex patterns in vast amounts of data, we can more effectively and efficiently develop innovative therapies for patients. Machine Learning Machine learning has been defined as the ...
Johnson & Johnson submits regulatory applications to European Medicines Agency for TREMFYA® (guselkumab) for treatment of patients with ulcerative colitis and Crohn's disease
May 01, 2024 Submission included data from the Phase 3 QUASAR program in ulcerative colitis and the Phase 3 GALAXI program in Crohn’s disease, which each achieved their primary endpoints [1], [2] Beerse, Belgium (May 1, 2024) – Janssen-Cilag International ...
TAR-210 results show 90% recurrence-free survival and 90% complete response in patients with high-risk and intermediate-risk non–muscle-invasive bladder cancer, respectively
May 05, 2024 Updated results reinforce the potential of TAR-210 to transform treatment of non – muscle-invasive bladder cancer with fibroblast growth factor receptor (FGFR) alterations SAN ANTONIO, May 5, 2024 – Johnson & Johnson announced today ...